沙特阿拉伯骨质疏松症药物市场，按类型（原发性骨质疏松症和继发性骨质疏松症）、药物（双膦酸盐、单克隆抗体、激素疗法和其他）、药物类型（品牌和通用）、给药途径（注射、口服和其他）、性别（女性和男性）、年龄组（老年病、成人和儿科）、最终用户（医院、专科诊所、家庭护理和其他）、分销渠道（直接招标、零售销售和其他）行业趋势和预测到 2029 年。
沙特阿拉伯骨质疏松症药物市场分析和见解
国际骨质疏松症基金会(IOF)认为:"骨质疏松"指多孔骨,是一种骨质和密度降低的疾病. 随着骨骼变得更加脆弱和多孔,骨折的风险也大大增加. 骨去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相去相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相相 在第一次骨折发生之前往往没有症状.
随着年龄的增长,部分骨细胞开始溶解骨基质,这一过程被称为再吸收,而新的骨细胞会沉淀出骨质,这一过程被称为形成. 这个过程被称为再造. 对于有骨质疏松症的人来说,骨损会快于新骨的生长. 骨骼变得脆,多孔并容易骨折. 虽然骨折也可能发生在其他骨骼上,但他最常见的骨折发生在手腕,脊椎或臀部.
不同种类的药物骨质疏松症可在市场上购买。 二磷酸盐通常是治疗骨质疏松症的首要选择. 其中包括:Risedronate(Actonel),每周或每月一粒药丸;Aledronate(Fosamax),每周一粒药丸;Zoledronic acid(Reclast),每年四分输液和Ibandronate(Boniva),每月一粒药丸或季度静脉注射(IV)输液.
数据桥市场研究分析认为,沙特阿拉伯骨质疏松症药物市场将在2022至2029年的预测期间以2.9%的CAGR增长.
|
报表计量 |
细节 |
|
预测期 |
2022至2029年统计 |
|
基准年 |
2021 |
|
历史年代 |
2020年(2019-2014年可定制). |
|
数量单位 |
收入(百万美元),定价(美元) |
|
覆盖部分 |
类型(初级骨质疏松症和二级骨质疏松症)、药物(双磷酸盐、单克隆抗体、荷尔蒙治疗等)、药物类型(布氏和通式)、管理路线(注射、口服等)、性别(男/女)、年龄组(儿科、成人和儿科)、最终用户(医院、专科诊所、家庭护理等)、分发渠道(直接招标、零售销售等) |
|
涵盖国家 |
沙特阿拉伯 |
|
覆盖的市场玩家 |
Eli Lilly and Company (美国)、Norvartis AG (瑞士)、Amgen Inc. (美国)、Tabuk (沙特阿拉伯)、SPIMACO (沙特阿拉伯)、Hikma PLC (约旦)、Pfize Inc. (美国)、Merck KGaA (德国)、Apotex Inc. (加拿大)、ABIOGEN PHARMA S.p.A. (意大利)、Sudair Pharma (沙特阿拉伯)、Tadawipha 。 (沙特阿拉伯)、Fresenius SE & Co. KGaA(德国)、Hayat制药业公司(约旦)和SAJA制药(沙特阿拉伯) |
骨质疏松症药物市场动态
司机
- 骨质疏松症发病率上升
骨质疏松症是一种骨质疾病,由于骨质矿物质密度和骨质质量较低或骨质质量或结构有一定差异而有所发展. 骨质疏松症可能增加骨折导致骨折的风险,因为骨骼强度降低.
比如说,
- 根据国际骨质疏松症基金会的统计,低骨质的流行程度在当时的中东和西方国家较高. 虽然骨质疏松症对男性和女性都有影响,但女性可能发展出骨质疏松症。
- 老年人口的增加
随着老年人口的增加,老年人口中骨质疏松症和骨病也在上升. 老龄化人口将指矫形中心,这将增加对骨质疏松症治疗的需求,因此预计将成为沙特阿拉伯骨质疏松症药物市场增长的动力。
机会
- 政府举措
骨质疏松症常被称作"静脉病",因为骨质流失是无痛和渐进的,通常没有症状表明一个人正在发展出骨质疏松症. 因此,政府正在采取主动行动,对国内的疾病进行早期隔离、诊断和治疗。 因此,作为未来几年市场增长的机会。
限制/挑战
然而,与骨质疏松症药物有关的副作用和治疗费用高将阻碍沙特阿拉伯骨质疏松症市场的增长。 此外,在改革保健系统方面进展缓慢,将在上述预测期间进一步挑战市场。
这份骨质疏松剂市场报告详细介绍了近期新发展,贸易监管,进出口分析,生产分析,价值链优化,市场份额,国内及本地市场主体影响等情况,分析了新兴收入口号,市场监管变化,战略性市场增长分析,市场规模,类别市场增长,应用优势和支配地位,产品审批,产品推出,地域扩张,市场技术创新等方面的机会. 为了获得更多关于实验室用品市场联系人 数据桥市场研究的信息 作为分析员简报 我们的团队将帮助你做出知情的市场决定 实现市场增长
患者流行病学分析
骨质疏松症是一种骨质疾病,由于骨质矿物质密度和骨质质量较低或骨质质量或结构有一定差异而有所发展. 据沙特阿拉伯卫生部统计,2018年,50岁以上人口的骨质疏松症流行率为37%.
根据医学科学研究国际期刊,2014年,82%的沙特女性患者患有维生素D缺乏症. 只有21%的妇女受到阳光照射,58%的妇女的BMD含量较低,其中18%患有骨质疏松症,40%患有骨质疏松症.
骨质疏松症药物市场也为您提供了详细的市场分析,病人分析,预后和治疗. 普遍程度、发生率、死亡率、遵守率是报告中现有的一些数据变量。 对流行病学对市场增长的直接或间接影响分析进行了分析,为预测增长期的市场创造了更有力和更相合的多变量统计模型。
COVID-19之后的影响实验室用品市场
COVID-19对市场产生了负面影响. 大流行病期间的封锁和隔离使疾病管理和药物坚持情况复杂化。 缺乏常规治疗和药品管理的保健设施将进一步影响市场。
最近的发展
- 2021年9月,希克玛药品PLC宣布,已同意收购Custopharm Inc.,以扩大公司的可注入和通用业务部分. Custopharm获得了美国FDA的13项批准,其中4项是先入市场的新药应用(ANDA)批准,包括一项具有竞争性通用疗法(CGT)名称的药品,以及1项小说505(b)(2) NDA批准。 这次收购帮助了公司增加了其产品组合并进一步增加了公司的总体收入.
沙特阿拉伯 骨质疏松症药物市场范围
骨质疏松症药物市场按类型、药物类型、药物类型、管理路线、性别、年龄组、最终用户和分销渠道分为八个值得注意的部分。 这些部门的增长将有助于你分析这些行业的微弱增长部门,并为用户提供宝贵的市场概况和市场见解,帮助他们作出确定核心市场应用的战略决定。
类型
- 初级骨质疏松症
- 二级骨质疏松.
根据类型,沙特阿拉伯骨质疏松症药物市场被分割为一级骨质疏松症和二级骨质疏松症.
药物
- 二磷酸盐
- 单体抗体
- 荷尔蒙治疗
- 其他人员
基于药物,沙特阿拉伯骨质疏松症药物市场被分解为双磷酸盐,单克隆抗体,激素疗法等.
药物类型
- 品牌
- 常规
根据药物类型,沙特阿拉伯骨质疏松症药物市场被分入品牌和通用.
行政路线
- 可注射
- 口头
- 其他人员
根据管理路线,沙特阿拉伯骨质疏松症药物市场分为可注射、口服等。
性别
- 妇女
- 男性
沙特阿拉伯的骨质疏松症药物市场按性别划分为女性和男性。
年龄组
- 老年病
- 成年人
- 儿科
根据年龄组,沙特阿拉伯骨质疏松症药物市场分为老年病、成人病和儿科。
结束用户
- 医院
- 专科诊所
- 家庭护理
- 其他人员
在最终用户的基础上,沙特阿拉伯骨质疏松症药物市场分为医院、专科诊所、家庭护理等。
分发频道
- 直接招标
- 零售
- 其他人员
根据分销渠道,沙特阿拉伯骨质疏松症药品市场分为直接招标、零售等。
管道分析
骨质疏松药物市场的输油管分析包括各种输油管疗法,如Ibandronate、Risedronate Sodium、Ibandroante(Bonviva/Boniva)、Strontium Ranelate等。 F. Hoffman-La Roche Ltd、Sanofi、Nycomed、Elly Lilly和Company以及北欧生物科学A/S等参与研制改进骨质疏松症治疗的潜在药物。
竞争性景观和骨质疏松症药物市场 共享分析
骨质疏松剂市场竞争性景观提供了由竞争者提供的细节. 详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、沙特阿拉伯的存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度、应用优势。 上述数据点仅与公司与骨质疏松症市场有关的重点有关。
在沙特阿拉伯骨质疏松症药物市场上经营的一些主要角色有:Eli Lilly and Company,Novartis AG,Amgen Inc.,Tabu克制药,SPIMACO,Hikma制药PLC,Pfize Inc.,Merck KGaA,Apotex Inc.,ABIOGEN PHARMA S.p.A.,Sudair Pharma,Tadawipharma.,Fresenius SE & Co. KGaA,Hayat制药工业公司等.
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
5 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PIPELINE ANALYSIS
6 REGULATIONS OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET
6.1 SUBMISSION
6.2 ASSESSMENT
7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, SUMMARY WRITE-UP
7.1 OVERVIEW
8 EPIDEMIOLOGY
8.1 EPIDEMIOLOGY - OSTEOPOROSIS
8.2 EPIDEMIOLOGY – RELATED INDICATIONS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN PREVALENCE OF OSTEOPOROSIS
9.1.2 RISE IN GERIATRIC POPULATION
9.2 RESTRAINTS
9.2.1 SIDE EFFECTS ASSOCIATED WITH OSTEOPOROSIS DRUGS
9.2.2 HIGH COST OF OSTEOPOROSIS TREATMENT
9.3 OPPORTUNITIES
9.3.1 GOVERNMENT INITIATIVES
9.3.2 RISE IN INCIDENCE OF SPORTS AND TRAUMA INJURIES
9.4 CHALLENGES
9.4.1 GAPS IN OSTEOPOROSIS PATIENT PATHWAY
10 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY TYPE
10.1 OVERVIEW
10.2 PRIMARY OSTEOPOROSIS
10.3 SECONDARY OSTEOPOROSIS
11 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS
11.1 OVERVIEW
11.2 BISPHOSPHONATES
11.2.1 ALENDRONATE
11.2.2 ZOLEDRONIC ACID
11.2.3 RISEDRONATE
11.2.4 IBANDRONATE
11.2.5 OTHERS
11.3 MONOCLONAL ANTIBODIES
11.3.1 DENOSUMAB
11.3.2 ROMOSOZUMAB
11.4 HORMONE THERAPY
11.4.1 PARATHYROID HORMONE (TERIPARATIDE)
11.4.2 ESTROGEN
11.4.2.1 CONJUGATED ESTROGENS
11.4.2.2 SELECTIVE ESTROGEN RECEPTOR MODULATORS
11.4.2.3 ESTERIFIED ESTROGENS
11.4.2.4 OTHERS
11.4.3 CALCITONIN
11.4.4 OTHERS
11.5 OTHERS
12 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 BRANDED
12.3 GENERIC
13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INJECTABLE
13.3 ORAL
13.3.1 TABLETS
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 OTHERS
14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY GENDER
14.1 OVERVIEW
14.2 FEMALE
14.3 MALE
15 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY AGE GROUP
15.1 OVERVIEW
15.2 GERIATRICS
15.3 ADULTS
15.4 PEDIATRICS
16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CLINICS
16.4 HOMECARE
16.5 OTHERS
17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 RETAIL SALES
17.3.1 HOSPITAL PHARMACY.
17.3.2 ONLINE RETAIL CHANNELS.
17.3.3 OTHER PHARMACY STORES.
17.4 OTHERS.
18 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: SAUDI ARABIA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 AMGEN INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENT
20.1.4.1 PRODUCT LAUNCH
20.2 ELI LILLY AND COMPANY
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 HIKMA PHARMACEUTICALS PLC
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENT
20.3.4.1 ACQUISITION
20.4 NOVARTIS AG
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.4.4.1 ACQUISITION
20.5 PFIZER INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ABIOGEN PHARMA S.P.A
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.3.1 PRODUCT LAUNCH
20.7 APOTEX INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.7.3.1 PRODUCT LAUNCH
20.8 FRESENIUS SE & CO. KGAA
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.8.4.1 INITIATION OF PHASE 3 TRIALS
20.9 HAYAT PHARMACEUTICAL INDUSTRIES CO. PLC
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.9.3.1 NEW PRODUCT LAUNCH
20.1 MERCK KGAA
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 SAJA PHARMACEUTICLAS
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 SPIMACO
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 SUDAIR PHARMA
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.13.3.1 ACQUISITION
20.14 TABUK PHARMACEUTICALS
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.14.3.1 ACQUISITION
20.15 TADAWIPHARMA
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PIPELINE ANALYSIS
TABLE 2 PROJECTED NUMBER OF OSTEOPOROSIS PATIENTS, BY COUNTRY, 2021-2026, (IN UNITS)
TABLE 3 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, DIAGNOSIS RATE, 2021-2026, (IN %)
TABLE 4 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, TREATMENT RATE, 2021-2026, (IN %)
TABLE 5 COST ESTIMATION OF PATIENTS WITH OSTEOPOROSIS
TABLE 6 ESTIMATED COST OF MEDICATIONS FOR THE TREATMENT OF OSTEOPOROSIS
TABLE 7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 9 SAUDI ARABIA BISPHOSPHONATES IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 10 SAUDI ARABIA MONOCLONAL ANTIBODIES IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 11 SAUDI ARABIA HORMONE THERAPY IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 12 SAUDI ARABIA ESTROGEN IN OSTEOPOROSIS DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION)
TABLE 13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION)
TABLE 14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 15 SAUDI ARABIA ORAL IN OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY GENDER, 2020-2029 (USD MILLION)
TABLE 17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 18 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 19 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 20 SAUDI ARABIA RETAIL SALES IN OSTEOPOROSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: SEGMENTATION
FIGURE 2 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DROC ANALYSIS
FIGURE 4 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: SEGMENTATION
FIGURE 11 RISE IN PREVALENCE OF OSTEOPOROSIS AND GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 PRIMARY OSTEOPOROSIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET IN 2022 & 2029
FIGURE 13 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PREVALENCE RATE AGED BETWEEN 50-79 YEARS, 2020
FIGURE 14 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, PROJECTED NUMBER OF OSTEOPOROSIS PATIENTS, (2021-2026)
FIGURE 15 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, DIAGNOSIS RATE, (2020-2026)
FIGURE 16 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, TREATMENT RATE, (2020-2026)
FIGURE 17 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, ADHERENCE RATE
FIGURE 18 OSTEOPOROSIS RELATED INDICATIONS, SAUDI ARABIA, 2020
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET
FIGURE 20 ANNUAL FEMUR FRACTURE RATE IN SAUDI ARABIAN POPULATION, PER 1,000,000 PERSONS-YEARS
FIGURE 21 OSTEOPOROSIS PATIENT JOURNEY IN KINGDOM OF SAUDI ARABIA
FIGURE 22 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, 2021
FIGURE 23 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 24 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 25 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 26 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, 2021
FIGURE 27 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION)
FIGURE 28 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, CAGR (2022-2029)
FIGURE 29 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 30 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, 2021
FIGURE 31 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, 2022-2029 (USD MILLION)
FIGURE 32 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, CAGR (2022-2029)
FIGURE 33 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 34 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 35 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 36 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 37 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, 2021
FIGURE 39 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, 2022-2029 (USD MILLION)
FIGURE 40 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, CAGR (2022-2029)
FIGURE 41 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 42 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, 2021
FIGURE 43 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, 2022-2029 (USD MILLION)
FIGURE 44 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 45 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 46 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, 2021
FIGURE 47 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 48 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 49 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 50 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 51 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 52 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 53 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 54 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
